Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds
| dc.contributor.author | Gloria M.A.J. | |
| dc.contributor.author | Thavorncharoensap M. | |
| dc.contributor.author | Chaikledkaew U. | |
| dc.contributor.author | Youngkong S. | |
| dc.contributor.author | Thakkinstian A. | |
| dc.contributor.author | Chaiyakunapruk N. | |
| dc.contributor.author | Ochalek J. | |
| dc.contributor.author | Culyer A.J. | |
| dc.contributor.correspondence | Gloria M.A.J. | |
| dc.contributor.other | Mahidol University | |
| dc.date.accessioned | 2024-02-08T18:20:12Z | |
| dc.date.available | 2024-02-08T18:20:12Z | |
| dc.date.issued | 2024-01-01 | |
| dc.description.abstract | Objective: Empirical estimates of the impact of healthcare expenditure on health outcome measures may inform the cost-effectiveness threshold (CET) for guiding funding decisions. This study aims to systematically review studies that estimated this, summarize and compare the estimates by country income level. Methods: We searched PubMed, Scopus, York Research database, and [anonymized] for Reviews and Dissemination database from inception to 1 August 2023. For inclusion, a study had to be an original article, estimating the impact of healthcare expenditure on health outcome measures at a country level, and presented estimates, in terms of cost per quality-adjusted life year (QALY) or disability-adjusted life year (DALY). Results: We included 18 studies with 385 estimates. The median (range) estimates were PPP$ 11,224 (PPP$ 223–PPP$ 288,816) per QALY gained and PPP$ 5,963 (PPP$ 71–PPP$ 165,629) per DALY averted. As ratios of Gross Domestic Product per capita (GDPPC), these estimates were 0.376 (0.041–182.840) and 0.318 (0.004–37.315) times of GDPPC, respectively. Conclusions: The commonly used CET of GDPPC seems to be too high for all countries, but especially low-to-middle-income countries where the potential health losses from misallocation of the same money are greater. Registration: The review protocol was published and registered in PROSPERO (CRD42020147276). | |
| dc.identifier.citation | Expert Review of Pharmacoeconomics and Outcomes Research Vol.24 No.2 (2024) , 203-215 | |
| dc.identifier.doi | 10.1080/14737167.2023.2296562 | |
| dc.identifier.eissn | 17448379 | |
| dc.identifier.issn | 14737167 | |
| dc.identifier.pmid | 38112068 | |
| dc.identifier.scopus | 2-s2.0-85180882369 | |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/96006 | |
| dc.rights.holder | SCOPUS | |
| dc.subject | Medicine | |
| dc.title | Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds | |
| dc.type | Review | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85180882369&origin=inward | |
| oaire.citation.endPage | 215 | |
| oaire.citation.issue | 2 | |
| oaire.citation.startPage | 203 | |
| oaire.citation.title | Expert Review of Pharmacoeconomics and Outcomes Research | |
| oaire.citation.volume | 24 | |
| oairecerif.author.affiliation | Ramathibodi Hospital | |
| oairecerif.author.affiliation | University of the Philippines Manila | |
| oairecerif.author.affiliation | University of York | |
| oairecerif.author.affiliation | VA Medical Center | |
| oairecerif.author.affiliation | Mahidol University | |
| oairecerif.author.affiliation | University of Utah Health |
